Peptides DB
Research-centric peptide and protocol reference hub
Study 21 of 22PT-141 (Bremelanotide) literatureThe journal of sexual medicine · Systematic review2026

Peptides for male sexual dysfunction: a systematic review of emerging evidence.

Melanocortin receptor agonists like PT-141 show promise for improving erectile function in men, but more research is needed to confirm their effectiveness and safety.

Read at The journal of sexual medicineAdd to compare

Where it sits

this study against the rest of the pt-141 (bremelanotide) corpus
6
Preclinical · this one
6
Observational
0
Open-label
3
Randomised
7
Reviews

Summary and findings

This systematic review evaluated the effects of peptide therapies on male sexual function, reproductive hormones, and semen parameters in adult men. A total of 372 male participants across twelve studies were included. The review found that melanocortin receptor agonists, including PT-141, showed consistent improvements in erectile function.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as The journal of sexual medicine supplied them

<h4>Background</h4>Sexual dysfunction remains highly prevalent among men and significantly impacts quality of life. Peptides are short chains of amino acids designed to mimic endogenous signaling molecules and modulate a variety of physiological pathways.<h4>Aim</h4>To systematically review the available human evidence evaluating the effects of peptide and peptide-derived therapies on male sexual function, reproductive hormones, and semen parameters.<h4>Methods</h4>A systematic review was conducted according to PRISMA guidelines. PubMed, Scopus, and Web of Science were searched. Eligible studies included randomized controlled trials, crossover studies, prospective clinical studies, and experimental physiological studies evaluating peptide-based interventions in adult men.<h4>Outcomes</h4>Outcomes of interest included erectile function, sexual desire, orgasmic and ejaculatory outcomes, reproductive hormones, semen parameters, and adverse events.<h4>Results</h4>Twelve studies comprising 372 male participants met inclusion criteria. Investigated peptides included melanocortin receptor agonists (PT-141/bremelanotide and Melanotan II), kisspeptin analogues, and oxytocin. Melanocortin receptor agonists demonstrated the most consistent improvements in erectile function, producing significant increases in penile rigidity and erectile duration in healthy men and men with erectile dysfunction, including sildenafil non-responders. Kisspeptin increased gonadotropin secretion, enhanced sexual brain processing, and improved penile tumescence and measures of sexual desire in men with hypoactive sexual desire disorder. Oxytocin showed mixed effects, with potential benefits on orgasm intensity, sexual satisfaction, and partner interaction, but no consistent improvements in erectile function, ejaculation latency, or semen parameters.<h4>Clinical implications</h4>Peptide-based interventions may influence male sexual health through distinct peripheral, central, endocrine, and relational mechanisms, offering potential adjuncts or second-line alternatives for men who have failed or are intolerant of first-line pharmacotherapy.<h4>Strengths and limitations</h4>Strengths include the synthesis of human clinical evidence across multiple peptide classes and principal domains of male sexual function. Overall, studies were limited by small sample sizes, heterogeneous populations, short follow-up durations, and a lack of comparative studies.<h4>Conclusion</h4>Melanocortin receptor agonists currently have the strongest evidence for improving erectile outcomes, while kisspeptin represents a promising emerging therapy for sexual desire and reproductive endocrine modulation. However, the evidence base remains limited, and further studies are required before these therapies can be incorporated into routine clinical practice.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the PT-141 (Bremelanotide) corpus

ACo-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.Urology · 2005 · Erectile response significantly greater with PT-141 and sildenafil vs sildenafil alone, p<0.05.HumanDMultifunctional material platforms for neural interfaces: active orchestration of dynamic foreign body response across implantation lifetimes.Bioactive materials · 2026reviewBAn interpretable machine learning model for predicting febrile seizures following enterovirus infection in children.Annals of medicine · 2026 · n=446 · XGBoost model training set AUC was 0.972 (95% CI: 0.958-0.987).HumanDReal-time sensing-integrated organoid-on-a-chip platforms: Technological progress and emerging biomedical applications.Bioactive materials · 2026reviewDSmart-responsive electrospun scaffolds (SRES) for neural repair: Recent advances and future prospects.Bioactive materials · 2026reviewAHMB supplementation combined with high-intensity functional exercise supports aerobic capacity but not strength in trained and untrained males: a randomized controlled trial.Journal of the International Society of Sports Nutrition · 2026 · n=90 · VO2MAX increased with HMB in TR, p=0.024.Human